-

Metrion Biosciences Strengthens Global Business Development Team

  • Two appointments in USA and Europe increase representation across key regions
  • Partnership established with On Target Drug Discovery Service and Supply, Ltd. to represent Metrion in Japan

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, today announced it has significantly enhanced its global business development capabilities, with additional resources now committed to support key regions in the USA, Europe and Japan.

Anca Haralambie has been appointed as Business Development Executive, representing Metrion in the UK and across Europe. Anca has broad experience of supporting clients in the global drug discovery sector, with particular expertise in translational research and induced pluripotent stem cells (iPSC).

Mari Kennedy will be supporting Metrion in the mid-west and east coast USA. Mari is an experienced ion channel sales and marketing executive, and joins Metrion’s west coast representatives Candidate Biopharma Advisors, to support the Company’s USA client base.

In Japan, Metrion will be represented by On Target Drug Discovery Service and Supply, Ltd. (On Target), based in Tokyo. On Target specialises in the sales and marketing of pre-clinical drug discovery services and related products from provider partners located outside of Japan, and will be working to support and expand upon Metrion’s customer base in the region.

Dr Andrew Southan, CEO, Metrion Biosciences, said: “Metrion has adopted an ambitious business plan to capitalise upon our unique position in the ion channel contract research arena. By strengthening our business development team we aim to raise further awareness of our capabilities in key territories and expand our portfolio of clients seeking to outsource high quality ion channel drug discovery and safety profiling services.”

Dr. Keiichi Yokoyama, founder and Managing Director, On Target, said: "On Target is pleased to support the expansion of Metrion's leading services portfolio within the Japan drug discovery community. We are fully committed to helping Metrion achieve its business goals in our territory by leveraging the Company’s scientific expertise with On-Target's market-specific experience and technical sales capability.

ENDS

Contacts

For further information and high-resolution images please contact:
For Metrion Biosciences
Katie Odgaard
Zyme Communications
E-mail: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947

Metrion Biosciences


Release Summary
Specialist ion channel CRO and drug discovery company Metrion Biosciences has significantly enhanced its global business development capabilities
Release Versions

Contacts

For further information and high-resolution images please contact:
For Metrion Biosciences
Katie Odgaard
Zyme Communications
E-mail: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947

More News From Metrion Biosciences

Metrion Biosciences Launches Nav1.9 High-Throughput Screening Assay to Strengthen Screening Portfolio and Advance Research on New Medicines for Pain

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a global leader in ion channel services, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics. Leveraging over a decade of electrophysiology expertise, the NaV1.9 assay, alongside Metrion’s unique combination of ion channel expertise, bespoke assays and pain researc...

Metrion Biosciences appoints Lee Patterson as CEO

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andre...

Metrion Biosciences Appoints Dr Chris Mathes as Chief Commercial Officer

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities. Following completion of Metrion’s £3.7M equity financing in December 20231,...
Back to Newsroom